Answers are grounded in this paper and cite their sources.
Calcitonin gene-related peptide (CGRP) is a pleiotropic neuropeptide widely expressed in the central and peripheral nervous systems, with established roles in neurovascular regulation, synaptic transmission, and neuroinflammation. While CGRP has been extensively characterized in migraine pathophysiology, its role in epilepsy remains incompletely defined and is primarily supported by experimental evidence. Preclinical studies consistently demonstrate CGRP upregulation following prolonged seizures, particularly in models of status epilepticus, and suggest that CGRP signaling may contribute to key processes implicated in epileptogenesis. These include modulation of neuronal excitability, blood-brain barrier permeability, and neuroimmune responses, such as microglial activation. At the same time, CGRP has been shown to engage neuroprotective pathways, including anti-apoptotic and anti-oxidative mechanisms, as well as barrier-stabilizing effects, supporting a complex and context-dependent role. Shared pathophysiological features between migraine and epilepsy, such as cortical hyperexcitability, neuroinflammation, and cortical spreading depolarization, provide a conceptual framework in which CGRP may act as a convergent mechanistic mediator. However, direct evidence in human epilepsy remains limited, and the translational relevance of these findings requires careful interpretation. This review provides a focused synthesis of mechanistic insights from experimental models, highlighting the dual role of CGRP in seizure-related processes and delineating current gaps in knowledge. Potential clinical implications, including the effects of CGRP-targeting therapies, are discussed in a hypothesis-generating context, with emphasis on the need for rigorous studies to clarify their relevance in epilepsy. PLAIN LANGUAGE SUMMARY: Migraine and epilepsy sometimes occur together and share changes in brain activity. This review examines CGRP, a signaling molecule involved in migraine, and its possible role in seizures. Animal studies suggest that CGRP can either increase abnormal brain activity and inflammation or protect nerve cells, depending on the conditions. Early observations in people raise the possibility that migraine medicines blocking CGRP could also affect seizures, but they do not prove a benefit. Further research is needed to determine whether these medicines can safely reduce seizures or prevent epilepsy.
No takes yet. Share an insight, caveat, or question.
Romozzi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: